Article Sidebar

PDF
Date Published: 25/12/2024
Online Published: 25/12/2024
Abstract Views: 12
Views PDF: 9
DOI: https://doi.org/10.58490/ctump.2024i82.2992
Issue
No. 82 (2024)
Section
Article
How to Cite
Nguyen, H. N., Nguyen, M. T., Nguyen, T. Y. D., Tran, T. M. H., Nguyen, H. V., & Lac, T. K. N. (2024). EVALUATION OF TREATMENT OUTCOMES FOR PLAQUE PSORIASIS USING CALCIPOTRIOL COMBINED WITH BETAMETHASONE AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY IN 2023-2024. Cantho Journal of Medicine and Pharmacy, 82, 116-122. https://doi.org/10.58490/ctump.2024i82.2992

EVALUATION OF TREATMENT OUTCOMES FOR PLAQUE PSORIASIS USING CALCIPOTRIOL COMBINED WITH BETAMETHASONE AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY IN 2023-2024

Hong Nhung Nguyen1,, Minh Tri Nguyen1, Thi Yen Duy Nguyen1, Thi Mai Huong Tran1, Hoang Viet Nguyen1, Thi Kim Ngan Lac1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: While benign, psoriasis is a common chronic skin condition that greatly impacts patients' quality of life. In Vietnam, calcipotriol combined with betamethasone is widely used for treating plaque psoriasis, but there are still very few studies evaluating the effectiveness of this treatment. Objectives: To evaluate the treatment outcomes of plaque psoriasis with topical calcipotriol combined with betamethasone. Materials and method: A cross-sectional description of 75 patients aged 16 and older diagnosed with mild to moderate plaque psoriasis under treatment with calcipotriol combined with betamethasone at Can Tho Hospital of Dermato-Venereology from July 2023 to July 2024. Results: After 4 weeks of treatment, there was a statistically significant reduction in PASI scores from weeks 2, 3, and 4 (p<0.001), indicating treatment efficacy is achieved starting from week 2 and continuing to improve in subsequent weeks. The average PASI score after 4 weeks of treatment was 5.3±1.5 (a reduction of 52.1±11%). The PASI reduction levels after week 4 were as follows: excellent 0%, good 4%, moderate 54.7%, fair 41.3%, and poor 0%. PASI 75 was achieved in 4% of cases, while PASI 50 was achieved in 58.7% of cases, corresponding to 4% of patients reaching the treatment goal and 58.7% of patients achieving minimal treatment efficacy. Itching and stinging were the only reported adverse effects, accounting for 8%. Conclusion: After 4 weeks of treatment, the proportion of patients achieving the treatment goal remains relatively low but is showing an upward trend. Therefore, more extensive and longer-term research with a larger sample size is needed to gather sufficient data to make a conclusive recommendation regarding this treatment protocol.

Article Details

Keywords

plaque psoriasis, treatment, calcipotriol, betamethasone, PASI

References

1. James G. H. Dinulos. Habif's Clinical Dermatology A Color Guide to Diagnosis and Therapy 7th Edition. Elsevier. 2021. 264-330.
2. Huỳnh Văn Bá và cộng sự. Bệnh vảy nến. Giáo trình Da liễu (Dành cho sinh viên y đa khoa, y học dự phòng, y học cổ truyền, răng hàm mặt). 2022. 53-66.
3. Hội Da Liễu Việt Nam. Hướng dẫn chăm sóc và điều trị bệnh vảy nến. Nhà xuất bản y học, Hà Nội. 2017.
4. Van Rossum M. M., Van Erp P. E. and Van de Kerkhof P. C. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology. 2001. 203(2), 148-152, https://doi.org/10.1159/000051730.
5. Patel N. U., Felix K., Reimer D. and Feldman S. R. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017. 10, 385-391, https://doi.org/10.2147/CCID.S131727.
6. Huang L., Ma L., Huang Q., Yang Q. P., Zeng Z. Z. et al. Calcipotriol betamethasone ointment in the treatment of psoriasis vulgaris: a randomized, double-blind, active-controlled, parallel group study. Chinese Journal of Dermatology. 2009. 42(10), 691–694.
7. Đặng Văn Em. Bệnh vảy nến. Một Số Bệnh Tự Miễn Dịch Thường Gặp Trong Da Liễu. 2014. 318-509.
8. Trần Nguyên Ánh Tú, Nguyễn Trọng Hào và Đặng Văn Em. Yếu tố liên quan và đặc điểm lâm sàng của bệnh nhân vảy nến thông thường đến khám tại Bệnh viện Da liễu Thành phố Hồ Chí Minh. Tạp chí Y Dược lâm sàng 108. 2020. 15(5), 1-5.
9. Lê Thị Hồng Thanh và Đặng Văn Em. Nghiên cứu một số yếu tố liên quan và đặc điểm lâm sàng bệnh vảy nến thông thường khám và điều trị tại Bệnh viện Da liễu Trung ương từ tháng 01/2018 đến tháng 12/2018. Tạp chí Y Dược lâm sàng 108. 2020. 15(3), 7-12.
10. Jo S. J., Park C. J., Bang C. H., Jeong K. H., Shin B. S. et al. Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction. The Journal of Dermatology. 2022. 49(11), 1085-1095, https://doi.org/10.1111/1346-8138.16519.
11. Anna C., Laura A., Concetta P., Giovanni D., Luca B. et al. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis:
The LION real‐life multicenter prospective observational cohort study. Dermatologic Therapy. 2021. 34(5), https://doi.org/10.1111/dth.15077.
12. Fouéré S., Adjadj L. and Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005. 19 Suppl 3, 2-6, https://doi.org/10.1111/j.14683083.2005.01329.x.
13. Paul C., Stein Gold L., Cambazard F., Kalb R. E., Lowson D. et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017. 31(1), 119-126, https://doi.org/10.1111/jdv.13859.